603259 药明康德
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入45,456,16615.84%40,340,80739,354,77822,902,38516,535,431
减:营业总成本29,148,1556.60%28,708,59129,800,81118,574,51613,928,304
    其中:营业成本23,801,4353.64%23,728,80024,677,21714,592,25610,253,276
               财务费用398,191-150.62%(338,119)(247,968)84,082519,804
               资产减值损失(541,556)-56.19%(156,509)(175,951)(33,056)(62,642)
公允价值变动收益(137,098)-173.33%(37,809)770,079(93,387)52,271
投资收益8,588,0171,321.47%233,849187,9491,356,269606,231
    其中:对联营企业和合营企业的投资收益452,58284.68%(67,560)(46,271)(117,290)(90,752)
营业利润23,930,084106.65%11,872,28610,652,2496,037,7253,389,485
利润总额23,906,151107.16%11,831,99110,618,4766,015,6093,369,376
减:所得税费用4,573,085131.89%2,131,7311,715,866879,662383,126
净利润19,333,066102.07%9,700,2608,902,6115,135,9472,986,250
减:非控股权益182,48355.40%93,51188,89838,79226,015
股东净利润19,150,582102.65%9,606,7498,813,7135,097,1552,960,235

市场价值指针
每股收益 (元) *6.700104.27%3.2703.0101.7501.060
每股派息 (元) *2.279132.18%0.9900.8930.5170.363
每股净资产 (元) *26.71531.59%18.57015.73713.02013.308
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容